• Collaboration aims to help patients worldwide gain access to a range of high-quality, affordable immunology and oncology biologics
• Partnership will be an important part of Sandoz and Biocon strategy to address the next wave of biosimilar opportunities globally
• Collaboration will leverage combined strengths of development, manufacturing and commercialization of biosimilars
• Partnership provides foundation for expansion of portfolio 

Holzkirchen, 18 January 2018 – Sandoz, a Novartis …